SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as its community rallies around the idea of OG meme season and community strength, emphasizing the value of shared culture over traditional financial metrics. Fueling the excitement is a collective push for increased visibility and a potential moonshot, with members actively coordinating efforts to trend and engage online. The broader narrative centers on reviving the spirit of early meme-based crypto projects.

Aventus Network

Aventus Network ($AVT) is trending, with community members citing its real-world technology and partnerships as potential catalysts. Discussions also highlight Aventus's integration with Polkadot and its possible listing on major exchanges like Binance. Some traders are comparing $AVT to $CTX, anticipating similar gains.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors debate its recent pullback and potential bottom, with some citing the overall downturn in AI stocks as a factor. Despite the volatility, the community expresses long-term confidence in the company's fundamentals, particularly its Microsoft deal and growth potential in the data center and AI infrastructure space. Bullish investors anticipate a rebound around earnings, while others are concerned about the lack of an official earnings date.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending downwards following its Q3 earnings release, with analysts pointing to a Brazilian tax dispute as a key factor impacting profitability. The community is actively debating whether this is a temporary setback or a sign of deeper issues, and if the company is overvalued. Some traders are anticipating further downgrades and a potential drop, while others see a buying opportunity amidst the uncertainty.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to recent news of a direct offering and its potential impact on the company's AI chip development, with discussions centering on whether the capital raise will fuel growth or dilute shareholder value. Some traders are pointing to the institutional investment as a positive signal, while others are concerned about the offering's timing after positive news. The community is also debating the validity and potential of the company's APU technology in comparison to industry giants.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending as investors react to a reported earnings beat and discuss the company's potential in AI data centers. Community members are highlighting the company's growth, with some expressing optimism about future price targets. Discussions also include the impact of Bitcoin's price movements and analyst ratings.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending after securing significant funding to advance its schizophrenia treatment through Phase 3 trials, sparking excitement about its potential. The community is actively discussing the implications of this funding for the company's future and the potential for a significant price increase. Some traders are wary, however, and point to prior dilution.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending due to a sharp decline following its Q3 earnings report, despite exceeding revenue expectations. Community discussions revolve around the company's cautious outlook and concerns about the automotive market, with some viewing the sell-off as an overreaction and a buying opportunity, while others point to valuation concerns and potential tariff impacts. The broader context involves renewed scrutiny on U.S.-China trade relations and their potential effect on the semiconductor industry.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen ($SG) is trending as investors discuss its high short interest and potential for a squeeze, alongside commentary around a recent CFO hire.  The stock is also garnering attention as a possible acquisition target, with some viewing the current price as oversold, while others cite expensive salads and profitability concerns.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following strong Q2 earnings, with significant procedure growth and increased da Vinci 5 placements driving positive sentiment. However, concerns persist within the community regarding margin pressures from tariffs and rising costs, leading to debates about the stock's valuation and future performance. Some traders are eyeing specific price levels for potential entries or exits, while others debate the long-term impact of competition and evolving healthcare trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mural Oncology PLC (MURA) and XOMA Royalty Corporation (XOMA) announced on Wednesday that they have entered into a definitive agreement under which a unit of XOMA will acquire Mural for cash.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.muraloncology.com/news-releases/news-release-details/mural-oncology-announces-entry-agreement-be-acquired-xra-5-corp">deal</a>, each Mural Shareholder would receive a cash price of between $2.035 and $2.24 per share. The base cash price represents a premium of approximately 13.1% to Mural’s closing share price of $1.80 on Tuesday. The additional price per share of up to $0.205 will be paid if Mural’s closing net cash exceeds estimates.MURA stock jumped 14% in the premarket session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MURA">Mural</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels. Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/XOMA">XOMA</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours.Mural's board of directors said that they have determined the acquisition and cash offer by XOMA, a biotechnology royalty aggregator, is in the best interest of all Mural shareholders. The board approved the acquisition and recommended that Mural shareholders vote in favor.The acquisition will be subject to the satisfaction of closing conditions, including approval by Mural shareholders. Excluding additional price per share, the deal values Mural at about $36.2 million.Mural Oncology announced plans to explore strategic alternatives in April after discontinuing all clinical development of Nemvaleukin. The decision followed data from a late-stage trial where Nemvaleukin in combination with Pembrolizumab did not achieve the primary endpoint of a statistically significant improvement in overall survival versus chemotherapy in platinum-resistant ovarian cancer. The company also saw no positive results from a mid-stage study of the drug in mucosal and cutaneous melanoma.MURA stock is down by 44% this year and over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Mural Oncology To Be Acquired By XOMA Royalty

The Mural board of directors said that they have determined the acquisition and cash offer by XOMA is in the best interest of all its shareholders. 

Equity

Mural Oncology Plc.'s stock (MURA) notched its best session ever on Tuesday, soaring nearly 134%, and extended gains in after-hours trading as the biotech firm said it was exploring strategic alternatives.The cancer drug maker said it would discontinue all clinical development of its lead drug candidate, nemvaleukin alfa, following disappointing data from two Phase 2 trials in melanoma and previously reported Phase 3 results in ovarian cancer.The company also said it had failed to meet the primary endpoint in its ARTISTRY-6 mucosal melanoma study, and preliminary data from a cutaneous melanoma cohort showed insufficient activity to continue.Mural said it plans to explore strategic alternatives, including a potential sale, merger, or other transaction, and has hired Lucid Capital Markets as its financial advisor.&nbsp;It has not received any offers or is in active discussions.&nbsp;As of Dec. 31, 2024, the company held about $144.4 million in cash and equivalents and will cut approximately 90% of its workforce as part of the strategic shift.The news sent message volume involving Mural Oncology on Stocktwits soaring by 62,000%, the highest among healthcare stocks, although sentiment plunged further into 'extremely bearish' territory.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/MURA_sentiment_and_message_volume_as_of_April_15_png_97c55d5bff.webp" alt="MURA sentiment and message volume as of April 15.png" width="1318" height="316"><figcaption>MURA sentiment and message volume as of April 15. | source: Stocktwits</figcaption></figure>Several skeptical retail watchers expect the stock to drop below $2 on Wednesday.<stembedurl>https://stocktwits.com/Smehran99/message/611776249</stembedurl><stembedurl>https://stocktwits.com/WMWilson/message/611761469</stembedurl>According to Koyfin, four analysts cover the stock, with two recommending a 'strong buy' and two with a 'hold' rating.Mural Oncology's stock has lost over a quarter of its valuation this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Mural Oncology's Retail Buzz Explodes After Micro-Cap Biotech Mulls Strategic Alternatives

The company will cut approximately 90% of its workforce as part of the strategic shift.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell...

Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H...

Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...

DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and...

Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference

DUBLIN, Ireland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...

DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein...

Mural Oncology Announces Enhancements to Late-Stage Clinical Trials

Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful data Mural intends to nominate development...

Mural Oncology Plc is a clinical-stage oncology company, which focuses on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.

Mural Oncology plc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

MURA
Mural Oncology plc

Feed

News

Sentiment

Fundamentals

Info

Latest MURA News

MURAMural Oncology plc